Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Identifieur interne : 000403 ( Main/Exploration ); précédent : 000402; suivant : 000404Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
Auteurs : Joachim Sieper [Allemagne] ; Désirée Van Der Heijde [Pays-Bas] ; Maxime Dougados [France] ; Philip J. Mease [États-Unis] ; Walter P. Maksymowych [Canada] ; Matthew A. Brown [Australie] ; Vipin Arora [États-Unis] ; Aileen L. Pangan [États-Unis]Source :
- Annals of the Rheumatic Diseases [ 0003-4967 ] ; 2013-06.
Abstract
Purpose To evaluate the efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods Patients fulfilled Assessment of Spondyloarthritis international Society (ASAS) criteria for axial spondyloarthritis, had a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥ 4, total back pain score of ≥ 4 (10 cm visual analogue scale) and inadequate response, intolerance or contraindication to non-steroidal anti-inflammatory drugs (NSAIDs); patients fulfilling modified New York criteria for ankylosing spondylitis were excluded. Patients were randomised to adalimumab (N=91) or placebo (N=94). The primary endpoint was the percentage of patients achieving ASAS40 at week 12. Efficacy assessments included BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS). MRI was performed at baseline and week 12 and scored using the Spondyloarthritis Research Consortium of Canada (SPARCC) index. Results Significantly more patients in the adalimumab group achieved ASAS40 at week 12 compared with patients in the placebo group (36% vs 15%, p<0.001). Significant clinical improvements based on other ASAS responses, ASDAS and BASDAI were also detected at week 12 with adalimumab treatment, as were improvements in quality of life measures. Inflammation in the spine and sacroiliac joints on MRI significantly decreased after 12 weeks of adalimumab treatment. Shorter disease duration, younger age, elevated baseline C-reactive protein or higher SPARCC MRI sacroiliac joint scores were associated with better week 12 responses to adalimumab. The safety profile was consistent with what is known for adalimumab in ankylosing spondylitis and other diseases. Conclusions In patients with nr-axSpA, adalimumab treatment resulted in effective control of disease activity, decreased inflammation and improved quality of life compared with placebo. Results from ABILITY-1 suggest that adalimumab has a positive benefit–risk profile in active nr-axSpA patients with inadequate response to NSAIDs.
Url:
DOI: 10.1136/annrheumdis-2012-201766
Affiliations:
- Allemagne, Australie, Canada, France, Pays-Bas, États-Unis
- Berlin, Hollande-Méridionale, Illinois, Washington (État)
- Berlin, Leyde, Paris, Seattle
- Université de Washington
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000787
- to stream Istex, to step Curation: 000787
- to stream Istex, to step Checkpoint: 000059
- to stream Main, to step Merge: 000403
- to stream Main, to step Curation: 000403
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)</title><author><name sortKey="Sieper, Joachim" sort="Sieper, Joachim" uniqKey="Sieper J" first="Joachim" last="Sieper">Joachim Sieper</name></author><author><name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name></author><author><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name></author><author><name sortKey="Mease, Philip J" sort="Mease, Philip J" uniqKey="Mease P" first="Philip J" last="Mease">Philip J. Mease</name></author><author><name sortKey="Maksymowych, Walter P" sort="Maksymowych, Walter P" uniqKey="Maksymowych W" first="Walter P" last="Maksymowych">Walter P. Maksymowych</name></author><author><name sortKey="Brown, Matthew A" sort="Brown, Matthew A" uniqKey="Brown M" first="Matthew A" last="Brown">Matthew A. Brown</name></author><author><name sortKey="Arora, Vipin" sort="Arora, Vipin" uniqKey="Arora V" first="Vipin" last="Arora">Vipin Arora</name></author><author><name sortKey="Pangan, Aileen L" sort="Pangan, Aileen L" uniqKey="Pangan A" first="Aileen L" last="Pangan">Aileen L. Pangan</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:EA6416A4B14B8FA035E33ADF5C25E41DC130AAEC</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1136/annrheumdis-2012-201766</idno><idno type="url">https://api.istex.fr/document/EA6416A4B14B8FA035E33ADF5C25E41DC130AAEC/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000787</idno><idno type="wicri:Area/Istex/Curation">000787</idno><idno type="wicri:Area/Istex/Checkpoint">000059</idno><idno type="wicri:doubleKey">0003-4967:2013:Sieper J:efficacy:and:safety</idno><idno type="wicri:Area/Main/Merge">000403</idno><idno type="wicri:Area/Main/Curation">000403</idno><idno type="wicri:Area/Main/Exploration">000403</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)</title><author><name sortKey="Sieper, Joachim" sort="Sieper, Joachim" uniqKey="Sieper J" first="Joachim" last="Sieper">Joachim Sieper</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Gastroenterology and Rheumatology, Charité Universitätsmedizin Berlin, Berlin</wicri:regionArea><placeName><region type="land" nuts="3">Berlin</region><settlement type="city">Berlin</settlement></placeName></affiliation></author><author><name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name><affiliation wicri:level="3"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Department of Rheumatology, Leiden University Medical Center, Leiden</wicri:regionArea><placeName><settlement type="city">Leyde</settlement><region nuts="2" type="province">Hollande-Méridionale</region></placeName></affiliation></author><author><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Rheumatology B Department, Paris-Descartes University, Medicine Faculty, Cochin Hospital, Paris</wicri:regionArea><placeName><settlement type="city">Paris</settlement></placeName></affiliation></author><author><name sortKey="Mease, Philip J" sort="Mease, Philip J" uniqKey="Mease P" first="Philip J" last="Mease">Philip J. Mease</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology Research, Swedish Medical Center, University of Washington, Seattle, Washington</wicri:regionArea><placeName><region type="state">Washington (État)</region><settlement type="city">Seattle</settlement></placeName><orgName type="university">Université de Washington</orgName></affiliation></author><author><name sortKey="Maksymowych, Walter P" sort="Maksymowych, Walter P" uniqKey="Maksymowych W" first="Walter P" last="Maksymowych">Walter P. Maksymowych</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University of Alberta, Edmonton</wicri:regionArea><wicri:noRegion>Edmonton</wicri:noRegion></affiliation></author><author><name sortKey="Brown, Matthew A" sort="Brown, Matthew A" uniqKey="Brown M" first="Matthew A" last="Brown">Matthew A. Brown</name><affiliation wicri:level="1"><country xml:lang="fr">Australie</country><wicri:regionArea>Human Genetics Group, University of Queensland Diamantina Institute, Princess Alexandra Hospital, Brisbane</wicri:regionArea><wicri:noRegion>Brisbane</wicri:noRegion></affiliation></author><author><name sortKey="Arora, Vipin" sort="Arora, Vipin" uniqKey="Arora V" first="Vipin" last="Arora">Vipin Arora</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Abbott Laboratories, Abbott Park, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Pangan, Aileen L" sort="Pangan, Aileen L" uniqKey="Pangan A" first="Aileen L" last="Pangan">Aileen L. Pangan</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Abbott Laboratories, Abbott Park, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of the Rheumatic Diseases</title><title level="j" type="abbrev">Ann Rheum Dis</title><idno type="ISSN">0003-4967</idno><idno type="eISSN">1468-2060</idno><imprint><publisher>BMJ Publishing Group Ltd and European League Against Rheumatism</publisher><date type="published" when="2013-06">2013-06</date><biblScope unit="volume">72</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="815">815</biblScope></imprint><idno type="ISSN">0003-4967</idno></series><idno type="istex">EA6416A4B14B8FA035E33ADF5C25E41DC130AAEC</idno><idno type="DOI">10.1136/annrheumdis-2012-201766</idno><idno type="href">annrheumdis-72-815.pdf</idno><idno type="ArticleID">annrheumdis-2012-201766</idno><idno type="PMID">22772328</idno><idno type="Related-article-href">10.1136/annrheumdis-2012-202389</idno><idno type="Related-article-href">10.1136/annrheumdis-2012-202908</idno><idno type="related-article-ID">RA1</idno><idno type="local">annrheumdis;72/6/815</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0003-4967</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract">Purpose To evaluate the efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis (nr-axSpA). Methods Patients fulfilled Assessment of Spondyloarthritis international Society (ASAS) criteria for axial spondyloarthritis, had a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score of ≥ 4, total back pain score of ≥ 4 (10 cm visual analogue scale) and inadequate response, intolerance or contraindication to non-steroidal anti-inflammatory drugs (NSAIDs); patients fulfilling modified New York criteria for ankylosing spondylitis were excluded. Patients were randomised to adalimumab (N=91) or placebo (N=94). The primary endpoint was the percentage of patients achieving ASAS40 at week 12. Efficacy assessments included BASDAI and Ankylosing Spondylitis Disease Activity Score (ASDAS). MRI was performed at baseline and week 12 and scored using the Spondyloarthritis Research Consortium of Canada (SPARCC) index. Results Significantly more patients in the adalimumab group achieved ASAS40 at week 12 compared with patients in the placebo group (36% vs 15%, p<0.001). Significant clinical improvements based on other ASAS responses, ASDAS and BASDAI were also detected at week 12 with adalimumab treatment, as were improvements in quality of life measures. Inflammation in the spine and sacroiliac joints on MRI significantly decreased after 12 weeks of adalimumab treatment. Shorter disease duration, younger age, elevated baseline C-reactive protein or higher SPARCC MRI sacroiliac joint scores were associated with better week 12 responses to adalimumab. The safety profile was consistent with what is known for adalimumab in ankylosing spondylitis and other diseases. Conclusions In patients with nr-axSpA, adalimumab treatment resulted in effective control of disease activity, decreased inflammation and improved quality of life compared with placebo. Results from ABILITY-1 suggest that adalimumab has a positive benefit–risk profile in active nr-axSpA patients with inadequate response to NSAIDs.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Australie</li><li>Canada</li><li>France</li><li>Pays-Bas</li><li>États-Unis</li></country><region><li>Berlin</li><li>Hollande-Méridionale</li><li>Illinois</li><li>Washington (État)</li></region><settlement><li>Berlin</li><li>Leyde</li><li>Paris</li><li>Seattle</li></settlement><orgName><li>Université de Washington</li></orgName></list><tree><country name="Allemagne"><region name="Berlin"><name sortKey="Sieper, Joachim" sort="Sieper, Joachim" uniqKey="Sieper J" first="Joachim" last="Sieper">Joachim Sieper</name></region></country><country name="Pays-Bas"><region name="Hollande-Méridionale"><name sortKey="Van Der Heijde, Desiree" sort="Van Der Heijde, Desiree" uniqKey="Van Der Heijde D" first="Désirée" last="Van Der Heijde">Désirée Van Der Heijde</name></region></country><country name="France"><noRegion><name sortKey="Dougados, Maxime" sort="Dougados, Maxime" uniqKey="Dougados M" first="Maxime" last="Dougados">Maxime Dougados</name></noRegion></country><country name="États-Unis"><region name="Washington (État)"><name sortKey="Mease, Philip J" sort="Mease, Philip J" uniqKey="Mease P" first="Philip J" last="Mease">Philip J. Mease</name></region><name sortKey="Arora, Vipin" sort="Arora, Vipin" uniqKey="Arora V" first="Vipin" last="Arora">Vipin Arora</name><name sortKey="Pangan, Aileen L" sort="Pangan, Aileen L" uniqKey="Pangan A" first="Aileen L" last="Pangan">Aileen L. Pangan</name></country><country name="Canada"><noRegion><name sortKey="Maksymowych, Walter P" sort="Maksymowych, Walter P" uniqKey="Maksymowych W" first="Walter P" last="Maksymowych">Walter P. Maksymowych</name></noRegion></country><country name="Australie"><noRegion><name sortKey="Brown, Matthew A" sort="Brown, Matthew A" uniqKey="Brown M" first="Matthew A" last="Brown">Matthew A. Brown</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000403 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000403 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:EA6416A4B14B8FA035E33ADF5C25E41DC130AAEC
|texte= Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1)
}}
| This area was generated with Dilib version V0.6.25. |  |